Abstract
Glioblastoma multiforme (GBM), the most common and aggressive form of primary brain tumor, presents a dismal prognosis. Current standard therapies are only able to improve patient survival by a few months. The search for alternative approaches in glioblastoma treatment, together with the recent discovery of a new class of small RNA molecules that are capable of regulating gene expression, prompted a race for a deeper and thorough understanding of how these molecules work. Today, it is known that microRNAs are involved in many cellular processes that are altered in GBM tumors, such as angiogenesis, invasion, cell proliferation and apoptosis. Research in this area is now gathering efforts to translate these findings into clinically relevant therapies that could improve the diagnosis and outcome of GBM patients. In this review, we discuss the use of microRNAs as potential diagnostic, prognostic and therapeutic tools against glioblastoma. We will also assess the current challenges and future perspectives of microRNA-based therapies, with a special focus on why this promising therapeutic approach is not yet in the clinic and how to overcome this limitation.
Keywords: Challenges, diagnostic, glioblastoma multiforme, microRNA, oncogenes, prognostic, therapeutic approaches, tumor suppressors
Current Molecular Medicine
Title:MicroRNA Targeting as a Therapeutic Strategy Against Glioma
Volume: 13 Issue: 4
Author(s): B. Auffinger, B. Thaci, A. Ahmed, I. Ulasov and M.S. Lesniak
Affiliation:
Keywords: Challenges, diagnostic, glioblastoma multiforme, microRNA, oncogenes, prognostic, therapeutic approaches, tumor suppressors
Abstract: Glioblastoma multiforme (GBM), the most common and aggressive form of primary brain tumor, presents a dismal prognosis. Current standard therapies are only able to improve patient survival by a few months. The search for alternative approaches in glioblastoma treatment, together with the recent discovery of a new class of small RNA molecules that are capable of regulating gene expression, prompted a race for a deeper and thorough understanding of how these molecules work. Today, it is known that microRNAs are involved in many cellular processes that are altered in GBM tumors, such as angiogenesis, invasion, cell proliferation and apoptosis. Research in this area is now gathering efforts to translate these findings into clinically relevant therapies that could improve the diagnosis and outcome of GBM patients. In this review, we discuss the use of microRNAs as potential diagnostic, prognostic and therapeutic tools against glioblastoma. We will also assess the current challenges and future perspectives of microRNA-based therapies, with a special focus on why this promising therapeutic approach is not yet in the clinic and how to overcome this limitation.
Export Options
About this article
Cite this article as:
Auffinger B., Thaci B., Ahmed A., Ulasov I. and Lesniak M.S., MicroRNA Targeting as a Therapeutic Strategy Against Glioma, Current Molecular Medicine 2013; 13 (4) . https://dx.doi.org/10.2174/1566524011313040006
DOI https://dx.doi.org/10.2174/1566524011313040006 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Prediction of the Ebola Virus Infection Related Human Genes Using Protein-Protein Interaction Network
Combinatorial Chemistry & High Throughput Screening Anti-Genes: siRNA, Ribozymes and Antisense
Current Pharmaceutical Biotechnology Use of Topiceuticals (Topically Applied, Peripherally Acting Drugs) in the Treatment of Chronic Pain
Current Drug Therapy CB1 Cannabinoid Receptors and their Associated Proteins
Current Medicinal Chemistry Histone Deacetylase Inhibitors as Potent Modulators of Cellular Contacts
Current Drug Targets Targeted Inhibition of Rictor/mTORC2 in Cancer Treatment: A New Era after Rapamycin
Current Cancer Drug Targets Bioconjugation of Ionophore Antibiotics: A Way to Obtain Hybrids with Potent Biological Activity
Mini-Reviews in Organic Chemistry Effect of O6-Substituted Guanine Analogs on O6-methylguanine DNA-methyltransferase Expression and Glioblastoma Cells Viability
Medicinal Chemistry Active-Targeted Nanotherapy Strategies for Prostate Cancer
Current Cancer Drug Targets Zinc Dependent Histone Deacetylase Inhibitors in Cancer Therapeutics: Recent Update
Current Medicinal Chemistry Mechanisms of Oxidative Glutamate Toxicity: The Glutamate/Cystine Antiporter System xc¯ as a Neuroprotective Drug Target
CNS & Neurological Disorders - Drug Targets Effect of PUFAs Oral Administration on the Amount of Apoptotic Caspases Enzymes in Gastric Cancer Patients Undergoing Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Identification of Phosphoproteins and their Impact as Biomarkers in Cancer Therapeutics
Current Signal Transduction Therapy Meet Our Editorial Board Member
Current Medicinal Chemistry Metabolomics and the Diagnosis of Human Diseases -A Guide to the Markers and Pathophysiological Pathways Affected
Current Medicinal Chemistry Inflammation and Cancer: In Medio Stat Nano
Current Medicinal Chemistry Phenylbutyric Acid: Simple Structure - Multiple Effects
Current Pharmaceutical Design Applications of Polymeric Nanocapsules in Field of Drug Delivery Systems
Current Drug Discovery Technologies Cytotoxic and Radio-sensitizing Effects of Polyphenolic Acetates in a Human Glioma Cell Line (BMG-1)
Current Pharmaceutical Design The Autism Candidate Gene Neurobeachin Encodes a Scaffolding Protein Implicated in Membrane Trafficking and Signaling
Current Molecular Medicine